LONDON (Alliance News) - BTG PLC Monday said it will start selling its drug-eluting bead and embolisation products, DC Bead and Bead Block, directly to customers in 11 European countries from April 1, 2015, a move that comes after it built up its direct sales force in the region for a different product.
The company's DC Bead and Bead Block products are currently sold in Europe by Terumo Corp, but that contract expires on March 31, 2015.
"BTG announced in May 2014 that it was expanding its commercial presence in Europe by building a direct sales force to promote the approved uses of its products in major European markets, initially to focus on the radioembolisation product TheraSphere. BTG has now decided that this sales force will also sell DC Bead and Bead Block, complementary interventional oncology products," it said in a statement.
Other European markets will be serviced by distributors working directly with BTG, it added.
By Steve McGrath; stevemcgrath@alliancenews.com; @stevemcgrath1
Copyright 2014 Alliance News Limited. All Rights Reserved.
